

Table S1 Baseline demographic and clinical features of training and validation cohorts.

Variables	Validation (n = 20)	Training(n = 80)	p
Age(year)	46 (32, 54.25)	42 (31.5, 51)	0.499
Sex			0.682
Female	73 (91)	17 (89)	
Man	7 (9)	2 (11)	
BMI(kg/m2)	21.83 $\pm$ 2.65	21.65 $\pm$ 2.5	0.775
Infection			0.685
No	70 (88)	18 (95)	
Yes	10 (12)	1 (5)	
Hypertension			1
No	75 (94)	18 (95)	
Yes	5 (6)	1 (5)	
Diabetes			1
No	77 (96)	19 (100)	
Yes	3 (4)	0 (0)	
Thyroid dysfunction			0.16
No	58 (72)	10 (53)	
Yes	22 (28)	9 (47)	
Symptom duration(month)	3 (0.42, 24)	2 (0.42, 30)	0.965
Dry mouth			0.79
No	41 (51)	11 (58)	
Yes	39 (49)	8 (42)	
Dry eyes			0.425
No	53 (66)	15 (79)	
Yes	27 (34)	4 (21)	
Rampant tooth			0.267
No	71 (89)	15 (79)	
Yes	9 (11)	4 (21)	
Fever			1
No	71 (89)	17 (89)	
Yes	9 (11)	2 (11)	
Arthrodynia			1
No	64 (80)	15 (79)	
Yes	16 (20)	4 (21)	
WBC(1*10 ⁹)	5.56 (3.77, 7.45)	5.3 (3.57, 5.8)	0.29
RBC(1*10 ¹²)	3.94 (3.57, 4.38)	3.78 (3.3, 4.48)	0.328
Hb(g/L)	117 (106, 130.25)	112 (99.5, 125.5)	0.315
PLT(1*10 ⁹)	204.5 (141, 268)	166 (61.5, 251.5)	0.17
ESR(mm/L)	48.82 (27, 53.75)	48.82 (48.82, 48.82)	0.079
CRP(mg/L)	5.39 (2.19, 16.62)	5.1 (2.37, 13.66)	0.8
Alkaline phosphatase(U/L)	81.5 (66, 103.25)	75 (66.5, 117)	0.897
IgG(g/L)	20.12 (14.58, 25.12)	20.17 (16.85, 28.4)	0.367

	24.89)		
IgA(g/L)	3.02 (2.37, 3.64)	2.91 (1.97, 3.62)	0.709
IgM(g/L)	1.54 (1.03, 1.75)	1.62 (1.17, 1.71)	0.641
C3(g/L)	0.92 $\pm$ 0.2	0.85 $\pm$ 0.16	0.112
C4(g/L)	0.2 (0.17, 0.23)	0.2 (0.14, 0.22)	0.334
RF			1
-	22 (28)	5 (26)	
+	58 (72)	14 (74)	
ANA			1
-	1 (1)	0 (0)	
+	79 (99)	19 (100)	
Anti-SSA			0.349
-	1 (1)	1 (5)	
+	79 (99)	18 (95)	
Anti-RO52			0.682
-	7 (9)	2 (11)	
+	73 (91)	17 (89)	
Anti-SSB			1
-	40 (50)	10 (53)	
+	40 (50)	9 (47)	
